Drug resistance and plasmid profile of uropathogenic Escherichia coli among urinary tract infection patients in Addis Abeba
Introduction: Urinary tract infection is a major cause of morbidity and mortality worldwide. Uropathogenic Escherichia coli bacteria are the most common cause of urinary tract infections. Drug resistant Escherichia coli is results in high levels of treatment failure and can be a significant threat to survival of patients.
Methodology: Escherichia coli bacteria were isolated using culture and conventional biochemical tests. Antimicrobial susceptibility testing and plasmid profile were performed using the Kirby Bauer disc diffusion method and plasmid analysis. Data was processed with SPSS version 16.0 and Epi-info version 3.4.1 software.
Results: The highest proportion of Escherichia coli isolates was resistant to (86.5%) to ampicillin, followed by ceftazidime (84%), ceftriaxone (80.5%), tetracycline (80%), trimethoprim-sulfamethoxazole (68.5%) and cefotaxime (66%). Escherichia coli isolates were most susceptible to meropenem (100%), imipenem (100%), amikacin (97.5%), nitrofurantoin (95%), ciprofloxacin (85.5%), norfloxacin (85%), chloramphenicol (83.5%), gentamycin (80%) and nalidixic acid (79%). Multidrug resistance (MDR) was observed in most (96.5%) E. coli isolates. Plasmid analysis revealed the presence of plasmid(s) in 165 (82.5%) of the E. coli isolates many of which had a plasmid size of 23 kb.
Conclusions: The overall incidence of antibiotic resistance (including MDR) among E. coli in this study was high to commonly used antibiotics, but no drug resistance to meropenem and imipenem was observed. Periodic monitoring of the drug resistance pattern is essential for better management of urinary tract infections, which has direct impact on the outcome of the patient.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).